Novel Therapies For Hematologic Malignancies

Diffuse large B-cell lymphoma (DLBCL)

Anti-CD19 CAR-T cell:

• Preferred for relapsed/refractory DLBCL if relapsed <1 year.

  • Tisagenlecleucel (tisa-cel)

  • Axicabtagene ciloleucel (axi-cel)

  • Lisocabtagene maraleucel (liso-cel)

  • Brexucabtagene autoleucel (brexu-cel)

Anti-CD19 mAb:

• Tafasitamab

Anti-CD20 mAb:

• Rituximab

• Obinutuzumab

Anti-CD79b ADC (Antibody-Drug Conjugate):

• Polatuzumab vedotin

  • Used in Pola-R-CHP regimen

Anti-CD19 ADC:

• Loncastuximab Tesirine

CD20 x CD3 Bispecific Ab:

• Engineered antibody that simultaneously binds to CD20 on B cells and CD3 on T cells → redirecting T cells to recognize and kill malignant B cells

  • Epcoritimab

  • Glofitamab

  • Mosunetuzumab

XPO1 inhibitor (nuclear exporter protein):

• Selinexor

Follicular Lymphoma/ Nodal Marginal Zone Lymphoma

Anti-CD19 CAR-T cell:

• Tisagenlecleucel (tisa-cel)

• Axicabtagene ciloleucel (axi-cel)

Anti-CD20 mAb:

• Obinutuzumab

• Rituximab

CD20 x CD3 Bispecific Ab:

• Epcoritimab

• Mosunetuzumab

EZH2 inhibitor:

• Tazametostat

  • For relapsed/refractory FL who have received at least two prior systemic therapies, regardless of EZH2 mutation status (better response in EZH2 mutated, but still derived benefit in wild type)

PI3K inhibitor:

• Copanlisib

Hodgkin Lymphoma

Anti-CD30 ADC:

• Brentuximab Vedotin

  • Used in BV-AVD regimen

PD-1 inhibitor:

• Nivolumab

• Pembrolizumab

Multiple Myeloma (MM)

Anti-CD38 mAb:

• Daratumumab

• Isatuximab

BCL-2 inhibitor:

• Venetoclax

B-cell maturation antigen (BCMA) CAR T-cell:

• Idecabtagene vicleucel (ide-cel)

• Ciltacabtagene autoleucel (cilta-cel)

BCMA x CD3 Bispecific Ab:

• Engineered T-cell engaging antibody that binds CD3 on T cells and BCMA on MM cells.

  • Teclistamab

  • Elranatamab

GPRC5D x CD3 Bispecific Ab:

• Engineered T-cell engaging antibody that binds CD3 on T cells and GPRC5D on MM cells.

  • Talquetamab

SLAMF7 mAb:

• Elotuzumab

Acute Lymphoblastic Leukemia (ALL)

Anti-CD19 mAb:

• Blinatumomab

Anti-CD22 ADC:

• Inotuzumab ozogamicin

Acute Myeloid Leukemia (AML)

Anti-CD33 ADC:

• Gemtuzumab ozogamicin

BCL-2 inhibitor:

• Venetoclax

FLT3 inhibitor:

• Midostaurin

• Quizartinib

• Gilteritinib

Hedgehog pathway inhibitor:

• Glasdegib

IDH inhibitor:

• IDH1 inhibitor:

  • Ivosidenib

  • Olutasidenib

• IDH2 inhibitor:

  • Enasidenib

Sezary Syndrome

Anti-CCR4 mAb:

• Mogamulizumab

Anti-CD30 ADC:

• Brentuximab Vedotin

Histone deacetylase (HDAC) inhibitor:

• Romidepsin

• Vorinostat